GT201200188A - Nuevos co-cristales de agomelatina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos co-cristales de agomelatina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
GT201200188A
GT201200188A GT201200188A GT201200188A GT201200188A GT 201200188 A GT201200188 A GT 201200188A GT 201200188 A GT201200188 A GT 201200188A GT 201200188 A GT201200188 A GT 201200188A GT 201200188 A GT201200188 A GT 201200188A
Authority
GT
Guatemala
Prior art keywords
crystals
pharmaceutical compositions
compositions containing
preparation procedure
agomelatine
Prior art date
Application number
GT201200188A
Other languages
English (en)
Inventor
Letellier Philippe
Lynch Michael
Pean Jean-Manuel
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46178495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200188(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR1101766A external-priority patent/FR2976284B1/fr
Application filed by Servier Lab filed Critical Servier Lab
Publication of GT201200188A publication Critical patent/GT201200188A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS CO-CRISTALES DE AGOMELATINA, LOS CUALES POR UNA PARTE SON AGONISTAS DE LOS RECEPTORES DEL SISTEMA MELATONINÉRGICO Y POR OTRA ANTAGONISTA DEL RECEPTOR 5-HT. ADEMÁS LA SOLICITUD SE RELACIONA A SU PROCEDIMIENTO DE PREPARACIÓN ASÍ COMO A LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
GT201200188A 2011-06-09 2012-06-08 Nuevos co-cristales de agomelatina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. GT201200188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1101766A FR2976284B1 (fr) 2011-06-09 2011-06-09 Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN201110245039 2011-08-25

Publications (1)

Publication Number Publication Date
GT201200188A true GT201200188A (es) 2013-11-18

Family

ID=46178495

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200188A GT201200188A (es) 2011-06-09 2012-06-08 Nuevos co-cristales de agomelatina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Country Status (44)

Country Link
US (1) US8710101B2 (es)
EP (1) EP2532647B1 (es)
JP (1) JP5525011B2 (es)
KR (1) KR20120138223A (es)
AR (1) AR086849A1 (es)
AU (1) AU2012203196C1 (es)
BR (1) BR102012013816B1 (es)
CA (1) CA2778850C (es)
CL (1) CL2012001501A1 (es)
CO (1) CO6580196A1 (es)
CR (1) CR20120287A (es)
CY (1) CY1118439T1 (es)
DK (1) DK2532647T3 (es)
EA (1) EA021386B1 (es)
EC (1) ECSP12011949A (es)
ES (1) ES2608799T3 (es)
GE (1) GEP20156339B (es)
GT (1) GT201200188A (es)
HR (1) HRP20161647T1 (es)
HU (1) HUE031266T2 (es)
IL (1) IL220066A0 (es)
JO (1) JO3213B1 (es)
LT (1) LT2532647T (es)
MA (1) MA34498B1 (es)
MD (1) MD4308C1 (es)
ME (1) ME02574B (es)
MX (1) MX2012006577A (es)
MY (1) MY159816A (es)
NI (1) NI201200101A (es)
PE (1) PE20130047A1 (es)
PH (1) PH12012000132A1 (es)
PL (1) PL2532647T3 (es)
PT (1) PT2532647T (es)
RS (1) RS55406B1 (es)
RU (1) RU2593749C2 (es)
SA (1) SA112330595B1 (es)
SG (1) SG186548A1 (es)
SI (1) SI2532647T1 (es)
SV (1) SV2012004235A (es)
TN (1) TN2012000266A1 (es)
TW (1) TWI441803B (es)
UY (1) UY34111A (es)
WO (1) WO2012168665A1 (es)
ZA (1) ZA201204184B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2429348T3 (es) * 2011-04-28 2013-11-14 Zentiva, K.S. Cocristales farmacéuticamente aceptables de N-[2-(7-metoxi-1-naftil)etil]acetamida y procedimientos para su preparación
ES2590908T3 (es) 2012-12-17 2016-11-24 Dr. Reddy's Laboratories Ltd. Cocristal de agomelatina con ácido fosfórico
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
PT2810656T (pt) * 2013-06-06 2017-11-13 Zentiva As Formulações de agomelatina compreendendo agomelatina na forma de cocristais
JP6595990B2 (ja) * 2013-07-29 2019-10-23 レ ラボラトワール セルヴィエ アゴメラチンとスルホン酸との新規な複合体、これらの製造方法及びこれらを含有する医薬組成物
WO2015013865A1 (en) * 2013-07-29 2015-02-05 Les Laboratoires Servier Agomelatine sulfonic acids complexes and preparation thereof
CN105473551B (zh) * 2013-07-31 2019-01-11 法国施维雅药厂 阿戈美拉汀和对甲苯磺酸的共晶的新形式、其制备方法和包含其的药物组合物
KR101404836B1 (ko) 2014-03-21 2014-06-09 순천향대학교 산학협력단 아고멜라틴의 공결정 및 그의 제조방법
KR101470794B1 (ko) 2014-06-30 2014-12-08 순천향대학교 산학협력단 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine
KR101790411B1 (ko) 2015-09-25 2017-10-26 순천향대학교 산학협력단 균일한 입도분포를 가지는 아고멜라틴 공결정 분체의 제조방법
WO2017115284A1 (en) * 2015-12-28 2017-07-06 Leiutis Pharmaceuticals Pvt, Ltd. Novel co-crystal forms of agomelatine
CA3027297A1 (en) * 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
CA3044802A1 (en) * 2016-11-23 2018-05-31 Bohne Askoy As Prevention and/or treatment of chronic fatigue syndrome
EP3466413A1 (en) * 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
WO2005063240A1 (en) * 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
WO2008035177A2 (en) * 2006-09-18 2008-03-27 Copharm Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
FR2908995B1 (fr) * 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101870662B (zh) * 2010-05-21 2013-03-20 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
WO2012046253A2 (en) * 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
ES2429348T3 (es) 2011-04-28 2013-11-14 Zentiva, K.S. Cocristales farmacéuticamente aceptables de N-[2-(7-metoxi-1-naftil)etil]acetamida y procedimientos para su preparación

Also Published As

Publication number Publication date
HRP20161647T1 (hr) 2017-02-10
PH12012000132B1 (en) 2014-10-20
EA201200728A1 (ru) 2013-04-30
CY1118439T1 (el) 2017-06-28
RU2013158816A (ru) 2015-07-20
LT2532647T (lt) 2016-11-25
BR102012013816B1 (pt) 2020-11-03
MX2012006577A (es) 2013-03-18
ECSP12011949A (es) 2012-07-31
JP5525011B2 (ja) 2014-06-18
US8710101B2 (en) 2014-04-29
GEP20156339B (en) 2015-08-10
MD20120050A2 (en) 2012-12-31
TN2012000266A1 (fr) 2013-12-12
EP2532647A1 (fr) 2012-12-12
SI2532647T1 (sl) 2017-01-31
CA2778850A1 (fr) 2012-12-09
TWI441803B (zh) 2014-06-21
ZA201204184B (en) 2013-02-27
KR20120138223A (ko) 2012-12-24
US20120316245A1 (en) 2012-12-13
JO3213B1 (ar) 2018-03-08
DK2532647T3 (en) 2017-01-16
HUE031266T2 (en) 2017-06-28
AR086849A1 (es) 2014-01-29
MA34498B1 (fr) 2013-09-02
NI201200101A (es) 2012-11-09
CA2778850C (fr) 2015-11-17
PE20130047A1 (es) 2013-02-10
WO2012168665A1 (fr) 2012-12-13
AU2012203196A1 (en) 2013-01-10
RU2593749C2 (ru) 2016-08-10
ES2608799T3 (es) 2017-04-17
MY159816A (en) 2017-02-15
EA021386B1 (ru) 2015-06-30
CR20120287A (es) 2013-08-09
RS55406B1 (sr) 2017-04-28
ME02574B (me) 2017-06-20
SA112330595B1 (ar) 2016-01-10
UY34111A (es) 2013-01-03
JP2013014584A (ja) 2013-01-24
CO6580196A1 (es) 2012-12-17
AU2012203196B2 (en) 2015-03-05
IL220066A0 (en) 2012-10-31
EP2532647B1 (fr) 2016-09-28
MD4308B1 (en) 2014-10-31
SV2012004235A (es) 2012-08-23
CL2012001501A1 (es) 2014-09-05
PH12012000132A1 (en) 2014-10-20
TW201302673A (zh) 2013-01-16
PT2532647T (pt) 2016-10-25
AU2012203196C1 (en) 2015-09-03
NZ600479A (en) 2013-10-25
MD4308C1 (ro) 2015-05-31
PL2532647T3 (pl) 2017-02-28
BR102012013816A2 (pt) 2013-07-30
SG186548A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
GT201200188A (es) Nuevos co-cristales de agomelatina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
GT201500093A (es) Moduladores de quinolinilo unidos a metileno de ror- gamma-t
GT201500233A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
GT201300196A (es) Moduladores del receptor de glucagón
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
CL2015002402A1 (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenergico asi como actividad antagonista del receptor muscarínico m3.
BR112016002459A8 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
BR112015012730A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
ECSP14013327A (es) Compuestos con actividad nematicida
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
DOP2012000135A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
CU24360B1 (es) Derivados de ácido heteroaril butanoico como inhibidores de lta4h
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
BR112017004742A2 (pt) 2-azabiciclos substituídos e seus usos como moduladores de receptor de orexina
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
DOP2013000307A (es) Antagonistas de trpv4
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
BR112013002846A2 (pt) derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
GT201400179A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio